1. Home
  2. PSMT vs ORKA Comparison

PSMT vs ORKA Comparison

Compare PSMT & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PriceSmart Inc.

PSMT

PriceSmart Inc.

HOLD

Current Price

$196.08

Market Cap

5.2B

ML Signal

HOLD

Logo Oruka Therapeutics Inc.

ORKA

Oruka Therapeutics Inc.

HOLD

Current Price

$87.30

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSMT
ORKA
Founded
1994
2004
Country
United States
United States
Employees
N/A
68
Industry
Department/Specialty Retail Stores
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.4B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
PSMT
ORKA
Price
$196.08
$87.30
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$92.50
AVG Volume (30 Days)
248.3K
1.3M
Earning Date
04-08-2026
05-13-2026
Dividend Yield
0.91%
N/A
EPS Growth
5.47
N/A
EPS
2.91
N/A
Revenue
$4,066,093,000.00
N/A
Revenue This Year
$12.29
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
$67.35
N/A
Revenue Growth
12.33
N/A
52 Week Low
$101.36
$10.97
52 Week High
$196.08
$91.00

Technical Indicators

Market Signals
Indicator
PSMT
ORKA
Relative Strength Index (RSI) 81.03 73.57
Support Level $120.37 $27.81
Resistance Level N/A $91.00
Average True Range (ATR) 4.92 4.74
MACD 1.35 2.27
Stochastic Oscillator 95.63 93.72

Price Performance

Historical Comparison
PSMT
ORKA

About PSMT PriceSmart Inc.

Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.

About ORKA Oruka Therapeutics Inc.

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Share on Social Networks: